Orforglipron in Australia: What Patients Need to Know Before It Arrives (2026)
| TL;DR |
| Orforglipron is an oral, once-daily GLP-1 weight loss tablet developed by Eli Lilly (brand name: Foundayo). It received FDA approval on 1 April 2026. Eli Lilly submitted a TGA application in Australia before the end of 2025. Australian approval is currently estimated for late 2026 to 2027. In the meantime, Mounjaro (tirzepatide) and Ozempic (semaglutide) are TGA-approved options available now through a telehealth GP consultation. |
Thousands of Australians are searching for orforglipron every month and for good reason.
It is a once-daily pill that works the same way as Ozempic and Mounjaro but does not require an injection. The FDA approved it in the United States in April 2026 under the brand name Foundayo. Eli Lilly confirmed a formal TGA submission was lodged in Australia before the end of 2025.
But orforglipron is not available in Australia yet. If you are waiting, this guide tells you exactly where things stand, what the evidence shows, and what weight loss options your GP can prescribe for you right now.
What Is Orforglipron and How Does It Work?
| Direct Answer |
| Orforglipron is a once-daily oral tablet that activates GLP-1 receptors in the brain to reduce appetite and slow gastric emptying. It is a small molecule (non-peptide) GLP-1 agonist, meaning it can be taken at any time without food or water restrictions, unlike oral semaglutide (Rybelsus). |
GLP-1 stands for glucagon-like peptide-1. It is a hormone your gut releases after eating that tells your brain you are full. Medications that mimic this hormone have changed the way doctors treat obesity because they address the biology of appetite, not just willpower.
What makes orforglipron different from existing GLP-1 medications is its form. Ozempic and Mounjaro are weekly injections. Rybelsus (oral semaglutide) is a daily tablet, but it must be taken on an empty stomach with only a small amount of water and you need to wait 30 minutes before eating or drinking anything else. Orforglipron has no such restrictions. You can take it with or without food, at any time of day.
It is manufactured as a small molecule rather than a peptide, which also makes it cheaper to produce. In the United States, Foundayo launched at approximately USD $149 per month, well below the cost of injectable GLP-1 medications.
Is Orforglipron Available in Australia Right Now?
| Direct Answer |
| No. Orforglipron is not currently available in Australia. The FDA approved it on 1 April 2026 in the United States. Eli Lilly lodged a TGA application in Australia before the end of 2025. Based on standard TGA review timelines, Australian approval is estimated between late 2026 and 2027. |
Before any medication can be prescribed in Australia, it must be approved by the Therapeutic Goods Administration (TGA). This process usually takes 12 to 18 months after submission.
In December 2025, an Eli Lilly spokesperson confirmed to The Medical Republic that a TGA submission for orforglipron for obesity and overweight management would be made before the end of 2025. Based on that timeline, clinicians and researchers estimate TGA approval around late 2026 to early 2027, though no official date has been confirmed.
Anyone claiming to prescribe or supply orforglipron in Australia right now is operating outside the TGA regulatory framework. Always check with an AHPRA-registered GP before starting any new weight management medication.
| Compliance Note (AHPRA) |
| This section reflects the regulatory status of orforglipron as of June 2026. Approval timelines may change. Holistica Health does not prescribe orforglipron and will not do so until TGA approval is granted and the medication is available through Australian pharmacies. Clinical review recommended before updating this section. |
What Do the Clinical Trials Show?
The evidence base for orforglipron is strong. Multiple Phase 3 trials have been completed across the ATTAIN and ACHIEVE programs.
Key findings from the ATTAIN obesity trials:
- At the highest dose (36mg), participants lost an average of approximately 9 to 12 percent of body weight over 72 weeks in the primary obesity studies.
- More than 67 percent of participants at the 36mg dose achieved weight loss of at least 5 percent.
- Nearly one in four participants at the 36mg dose lost 15 percent or more of their body weight.
- The ATTAIN-MAINTAIN trial showed that switching from injectable GLP-1 therapy to oral orforglipron maintained weight loss over 52 additional weeks.
The safety profile is consistent with the GLP-1 class. The most common side effects are gastrointestinal: nausea, diarrhoea, and vomiting. These are typically mild to moderate and tend to resolve as your body adjusts. There were no hepatic safety concerns identified in the completed trials.
For patients with type 2 diabetes, the ACHIEVE trials showed meaningful reductions in HbA1c, with participants at the highest dose achieving up to a 2.1 percent reduction compared to placebo.
How Does Orforglipron Compare to Mounjaro and Ozempic?
This is the question most patients ask. Here is a plain-English comparison based on the available evidence.
| Feature | Orforglipron (Foundayo) | Mounjaro (tirzepatide) | Ozempic (semaglutide) |
|---|---|---|---|
| Form | Daily tablet | Weekly injection | Weekly injection |
| TGA Approved? | No (submitted, pending) | Yes (Sept 2024) | Yes |
| US Cost (approx.) | ~USD $149/month | ~USD $1,060/month | ~USD $935/month |
| Avg. weight loss (Phase 3) | 9 to 12% at max dose | 15 to 22% | 10 to 15% |
| Food restrictions | None | None | None |
| Mechanism | GLP-1 agonist | GIP + GLP-1 dual agonist | GLP-1 agonist |
| Available in Australia now? | No | Yes | Yes |
Mounjaro (tirzepatide) currently shows higher average weight loss in trials because it acts on two hormone pathways simultaneously: GLP-1 and GIP. However, orforglipron is expected to be considerably cheaper and does not require an injection or refrigeration, which may make it a better fit for patients who travel frequently, live in remote areas, or have needle anxiety.
If you want to start a medically supervised weight loss program now, you can book a weight loss consultation with one of our AHPRA-registered GPs online. Mounjaro and Ozempic prescriptions are available through Holistica Health following a clinical assessment.
What Should You Do While Waiting for Orforglipron in Australia?
| Direct Answer |
| If you are considering GLP-1 therapy for weight loss, you do not need to wait. Mounjaro (tirzepatide) and Ozempic (semaglutide) are both TGA-approved, available now through AHPRA-registered GPs, and supported by strong clinical evidence. A telehealth GP can assess your eligibility, review your medical history, and issue a prescription in a single online consultation. |
Here is what a practical path forward looks like:
- Complete a pre-screening eligibility check. This takes about two minutes and confirms that a telehealth consultation is appropriate for your situation.
- Book an initial weight loss consultation. At Holistica Health, this costs $99 and covers a full clinical assessment, including relevant screening for GLP-1 suitability.
- Discuss your options. Your GP will review your BMI, medical history, current medications, and any relevant risk factors before recommending a treatment approach.
- Start your program. If prescribed, Mounjaro and Ozempic are available at pharmacies across Australia. Your GP will provide ongoing follow-up consultations as you progress.
You are not giving anything up by starting now. If orforglipron becomes available in Australia and your GP considers it a better clinical fit for you, that is a conversation you can have at a follow-up consultation.
Who Is Orforglipron Likely to Be Prescribed For in Australia?
Based on the FDA indication and the clinical trial criteria, orforglipron is expected to be indicated for:
- Adults with obesity (BMI of 30 or above), or
- Adults who are overweight (BMI of 27 or above) with at least one weight-related health condition, such as type 2 diabetes, high blood pressure, or high cholesterol, in combination with a reduced-calorie diet and increased physical activity.
This matches the current prescribing criteria for Mounjaro and Ozempic in Australia, so if you are eligible for those medications now, you are likely to be eligible for orforglipron once it receives TGA approval.
One patient group that may particularly benefit from orforglipron is those who struggle with weekly self-injections. Needle anxiety is a real barrier for many patients, and a daily tablet with no food restrictions removes that friction entirely.
The Bottom Line on Orforglipron in Australia
Orforglipron is a genuinely promising oral weight loss medication. The FDA approved it in April 2026. Eli Lilly has lodged a TGA application in Australia, and approval is expected between late 2026 and 2027.
But if managing your weight is a priority for you right now, you do not need to wait for a new drug. Mounjaro and Ozempic are available today through a 30-minute telehealth consultation with an AHPRA-registered GP. The initial consultation at Holistica Health costs $99 and covers a full clinical assessment.
| Ready to Start? Book Your Weight Loss Consultation Today |
| Holistica Health offers online weight loss consultations for patients across Australia, including Perth, WA, QLD, VIC, and NSW. No GP referral required. Initial consultation: $99. Book your pre-screening check and get assessed this week. |
Frequently Asked Questions About Orforglipron in Australia
When will orforglipron be available in Australia?
Eli Lilly lodged a TGA application for orforglipron in Australia before the end of 2025. Based on standard TGA review periods of 12 to 18 months, Australian approval is estimated between late 2026 and 2027. No official approval date has been confirmed by the TGA or Eli Lilly as of the date this article was published.
Is orforglipron the same as Ozempic or Mounjaro?
No. Ozempic (semaglutide) is a weekly injection that acts on GLP-1 receptors. Mounjaro (tirzepatide) is a weekly injection that acts on both GLP-1 and GIP receptors. Orforglipron is a once-daily oral tablet that acts on GLP-1 receptors. All three reduce appetite and support weight loss, but their mechanisms, forms, and cost profiles differ. Mounjaro currently shows higher average weight loss in clinical trials.
Can a telehealth GP prescribe orforglipron in Australia right now?
No. Orforglipron is not TGA-approved in Australia as of June 2026 and cannot be legally prescribed here. Any clinic claiming to prescribe it in Australia is operating outside the regulatory framework. An AHPRA-registered telehealth GP can prescribe TGA-approved weight loss medications, including Mounjaro and Ozempic, following a clinical assessment.
How much will orforglipron cost in Australia?
No Australian pricing has been confirmed. In the United States, it launched at approximately USD $149 per month (around AUD $230 at current exchange rates). This is significantly below the cost of injectable GLP-1 medications in Australia. However, whether orforglipron will be listed on the Pharmaceutical Benefits Scheme (PBS) in Australia, which would reduce patient costs substantially, is not yet known.
What is the difference between a peptide and a non-peptide GLP-1?
Peptide GLP-1 medications like oral semaglutide (Rybelsus) are made from protein-like chains that are broken down by stomach acid, which is why they require strict fasting and small-volume water restrictions to ensure absorption. Orforglipron is a small molecule (non-peptide) GLP-1 agonist. It is chemically stable and absorbed normally, so it can be taken with or without food at any time, making it significantly easier to incorporate into a daily routine.